PacBio Books Five Systems as Revenues Climb 164 Percent | GenomeWeb

This article was originally published Oct. 23.

Pacific Biosciences booked orders for five of its PacBio RS II systems in the third quarter of 2013, bringing in $7.4 million in revenues and beating the consensus Wall Street estimate of $7.1 million in revenues for the quarter.

PacBio CEO Mike Hunkapiller attributed the recent uptick to customers' published studies demonstrating the system's ability to generate long, accurate reads for de novo assembly applications and to sequence hard to sequence regions of complex genomes.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."